CSF2 and pancreatic neoplasm: For example, the clinical trial of NCT01274455 showed the safety of administration of non-viral gene product of CYL-02, which encodes mouse somatostatin receptor subtype 2 and a fusion gene of deoxycytidine kinase and monophosphate kinase, which could sensitize the cancer cells to gemcitabine [44] and the clinical trial of NCT00836407 evaluated the effect of granulocyte-macrophage colony stimulating factor gene-delivered pancreatic tumor cells with the ipilimumab [47].